News, Resources, Updates
A scientific hub to keep you informed about our latest research and company updates.
Project Completion Announcement: CARDIOIDS Collaboration with Professor Leon de Windt Advances Arrhythmogenic Cardiomyopathy (ACM) Research
In its role as an industry research partner, InnoSer is pleased to announce the successful completion of the CARDIOIDS project, a consortium-led initiative led by Professor Leon de Windt at Maastricht University. This project represents a major milestone in...
InnoSer and TissUse Sign Strategic Co-Marketing Agreement to Advance Microphysiological Systems (MPS) Applications in Drug Development
InnoSer, a leading preclinical contract research organization (CRO), and TissUse, a pioneer in the field of microphysiological systems (MPS) development, are pleased to announce the signing of a strategic co-marketing agreement aimed at promoting the widespread...
Therapeutic targets for ADPKD
In ADPKD, mutations in the PKD1 or PKD2 gene cause changes in polycystin 1 or 2 (PC1 and PC2) expression, which in turn interferes with several intracellular signaling pathways that are e.g., involved in cell proliferation, fluid secretion, and ciliary function. The...
InnoSer completes a major milestone in the HEAL project with validated tumorigenicity assay
In a significant achievement, InnoSer has successfully validated tumorigenicity assay as part of the HEAL project, a major initiative aimed at accelerating the development of an allogeneic iPSC-based heart therapy. This milestone lays out the groundwork for safe and...
Exploring InnoSer’s Key In vitro Oncology Services: PD-1 PD-L1 Blockade Assay
Immune Checkpoint Blockade in Oncology Drug Discovery In recent years, immune checkpoint blockade has emerged as a groundbreaking therapeutic strategy in immuno-oncology. Programmed cell death 1 receptor (PD-1), and its ligand programmed cell death ligand 1 (PD-L1)...
InnoSer Announces Joint Initiative with Hasselt University/BIOMED to Support Preclinical Multiple Sclerosis Research
Researchers will benefit from InnoSer’s preclinical drug development expertise combined with Hasselt University’s foundational knowledge in Multiple Sclerosis (MS) to advance preclinical MS research. Diepenbeek, Belgium, October 16th, 2024 — InnoSer, a leading...
info@innoserlaboratories.com